125 related articles for article (PubMed ID: 33734721)
1. Engineered Antibody Fragment against the Urokinase Plasminogen Activator for Fast Delineation of Triple-Negative Breast Cancer by Positron Emission Tomography.
Lu W; Cong Y; Yang D; Chen D; Yang G; Wang Y; Van Dort ME; Ross BD; Mazar AP; Chu BB; Hong H
Mol Pharm; 2021 Apr; 18(4):1690-1698. PubMed ID: 33734721
[TBL] [Abstract][Full Text] [Related]
2. Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging.
Yang D; Severin GW; Dougherty CA; Lombardi R; Chen D; Van Dort ME; Barnhart TE; Ross BD; Mazar AP; Hong H
Oncotarget; 2016 Nov; 7(45):73912-73924. PubMed ID: 27729618
[TBL] [Abstract][Full Text] [Related]
3. Positron emission tomography imaging of tumor angiogenesis with a (61/64)Cu-labeled F(ab')(2) antibody fragment.
Hong H; Zhang Y; Orbay H; Valdovinos HF; Nayak TR; Bean J; Theuer CP; Barnhart TE; Cai W
Mol Pharm; 2013 Feb; 10(2):709-16. PubMed ID: 23316869
[TBL] [Abstract][Full Text] [Related]
4. Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507.
Heskamp S; van Laarhoven HW; Molkenboer-Kuenen JD; Bouwman WH; van der Graaf WT; Oyen WJ; Boerman OC
Mol Pharm; 2012 Aug; 9(8):2314-21. PubMed ID: 22747077
[TBL] [Abstract][Full Text] [Related]
5. MicroPET/CT imaging of patient-derived pancreatic cancer xenografts implanted subcutaneously or orthotopically in NOD-scid mice using (64)Cu-NOTA-panitumumab F(ab')2 fragments.
Boyle AJ; Cao PJ; Hedley DW; Sidhu SS; Winnik MA; Reilly RM
Nucl Med Biol; 2015 Feb; 42(2):71-7. PubMed ID: 25456837
[TBL] [Abstract][Full Text] [Related]
6.
Kang L; Li C; Yang Q; Sutherlin L; Wang L; Chen Z; Becker KV; Huo N; Qiu Y; Engle JW; Wang R; He C; Jiang D; Xu X; Cai W
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1470-1481. PubMed ID: 34677626
[TBL] [Abstract][Full Text] [Related]
7. Glypican-3-targeting F(ab')2 for 89Zr PET of hepatocellular carcinoma.
Sham JG; Kievit FM; Grierson JR; Chiarelli PA; Miyaoka RS; Zhang M; Yeung RS; Minoshima S; Park JO
J Nucl Med; 2014 Dec; 55(12):2032-7. PubMed ID: 25359880
[TBL] [Abstract][Full Text] [Related]
8. Antibody Fragment F(ab')
Li Q; Peterson N; Hanna RN; Kuszpit K; White J; Allen KL; Barnes A; Rickert KW; Shan L; Wu H; Dall'Acqua WF; Tsui P; Borrok MJ
Mol Pharm; 2020 Feb; 17(2):507-516. PubMed ID: 31841002
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive Evaluation of CD20 Expression Using
Kang L; Li C; Rosenkrans ZT; Engle JW; Wang R; Jiang D; Xu X; Cai W
J Nucl Med; 2021 Mar; 62(3):372-378. PubMed ID: 32826320
[TBL] [Abstract][Full Text] [Related]
10. Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody.
Khawli LA; Alauddin MM; Hu P; Epstein AL
Cancer Biother Radiopharm; 2003 Dec; 18(6):931-40. PubMed ID: 14969605
[TBL] [Abstract][Full Text] [Related]
11. PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors.
Hoeben BA; Kaanders JH; Franssen GM; Troost EG; Rijken PF; Oosterwijk E; van Dongen GA; Oyen WJ; Boerman OC; Bussink J
J Nucl Med; 2010 Jul; 51(7):1076-83. PubMed ID: 20554724
[TBL] [Abstract][Full Text] [Related]
12. Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts.
Lütje S; van Rij CM; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
Contrast Media Mol Imaging; 2015; 10(1):28-36. PubMed ID: 24764162
[TBL] [Abstract][Full Text] [Related]
13.
Cheng Y; Shi D; Xu Z; Gao Z; Si Z; Zhao Y; Ye R; Fu Z; Fu W; Yang T; Xiu Y; Lin Q; Cheng D
Mol Pharm; 2022 Oct; 19(10):3551-3562. PubMed ID: 35244407
[TBL] [Abstract][Full Text] [Related]
14. Preparation, characterization, and in vivo biodistribution properties of synthetically cross-linked multivalent antitumor antibody fragments.
Schott ME; Frazier KA; Pollock DK; Verbanac KM
Bioconjug Chem; 1993; 4(2):153-65. PubMed ID: 7873647
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibody Fab' fragment cross-linking using equilibrium transfer alkylation reagents. A strategy for site-specific conjugation of diagnostic and therapeutic agents with F(ab')2 fragments.
Wilbur DS; Stray JE; Hamlin DK; Curtis DK; Vessella RL
Bioconjug Chem; 1994; 5(3):220-35. PubMed ID: 7918742
[TBL] [Abstract][Full Text] [Related]
16. Biodistribution properties of (111)indium-labeled C-functionalized trans-cyclohexyl diethylenetriaminepentaacetic acid humanized 3S193 diabody and F(ab')(2) constructs in a breast carcinoma xenograft model.
Tahtis K; Lee FT; Smyth FE; Power BE; Renner C; Brechbiel MW; Old LJ; Hudson PJ; Scott AM
Clin Cancer Res; 2001 Apr; 7(4):1061-72. PubMed ID: 11309358
[TBL] [Abstract][Full Text] [Related]
17. Noninvasive localization of experimental atherosclerotic lesions with mouse/human chimeric Z2D3 F(ab')2 specific for the proliferating smooth muscle cells of human atheroma. Imaging with conventional and negative charge-modified antibody fragments.
Narula J; Petrov A; Bianchi C; Ditlow CC; Lister BC; Dilley J; Pieslak I; Chen FW; Torchilin VP; Khaw BA
Circulation; 1995 Aug; 92(3):474-84. PubMed ID: 7634463
[TBL] [Abstract][Full Text] [Related]
18. The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab')₂-R1507 fragments in Ewing sarcomas.
Fleuren ED; Versleijen-Jonkers YM; Heskamp S; Roeffen MH; Bouwman WH; Molkenboer-Kuenen JD; van Laarhoven HW; Oyen WJ; Boerman OC; van der Graaf WT
Eur J Cancer; 2013 Sep; 49(13):2851-8. PubMed ID: 23664098
[TBL] [Abstract][Full Text] [Related]
19. A cross-linked monoclonal antibody fragment for improved tumor targeting.
Stalteri MA; Mather SJ
Bioconjug Chem; 1995; 6(2):179-86. PubMed ID: 7599261
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]